Effects of inhibiting neutral endopeptidase and kininase II on coronary and systemic hemodynamics in rats
- PMID: 7573497
- DOI: 10.1152/ajpheart.1995.269.3.H1016
Effects of inhibiting neutral endopeptidase and kininase II on coronary and systemic hemodynamics in rats
Abstract
To determine whether neutral endopeptidase (NEP) and kininase II (angiotensin-converting enzyme, ACE) influence coronary hemodynamics, we compared the effects of inhibiting NEP, ACE, or both before and after isoproterenol (50 mg/kg ip). We measured flow and resistance using radioactive microspheres in 90 anesthetized rats which received the NEP inhibitor phosphoramidon (2.5 mg/kg), the ACE inhibitor captopril (2.5 mg/kg), both combined, or vehicle alone. Before isoproterenol, inhibiting NEP, ACE, or both increased left ventricular blood flow by 48 +/- 10 (SE), 33 +/- 9, and 10 +/- 6%, respectively, and decreased left ventricular vascular resistance by 26 +/- 6, 31 +/- 10, and 10 +/- 6%, respectively. After isoproterenol, NEP inhibition augmented the decrease in left ventricular vascular resistance (25 +/- 6% decrease within 90 s of isoproterenol vs. 8 +/- 5% in controls). ACE inhibition did not augment the decrease in resistance but inhibiting both enzymes did so to a lesser extent than inhibiting NEP. These effects cannot be explained by vascular responses secondary to changes of myocardial oxygen consumption. We conclude that NEP and ACE are regulators of myocardial blood flow.
Similar articles
-
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.J Pharmacol Exp Ther. 1998 Nov;287(2):567-77. J Pharmacol Exp Ther. 1998. PMID: 9808682
-
Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.J Pharmacol Exp Ther. 1995 Nov;275(2):745-52. J Pharmacol Exp Ther. 1995. PMID: 7473162
-
Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation.Circ Res. 1994 Oct;75(4):770-9. doi: 10.1161/01.res.75.4.770. Circ Res. 1994. PMID: 7923622
-
Vasopeptidase inhibition: a double-edged sword?Hypertension. 2003 Mar;41(3):383-9. doi: 10.1161/01.HYP.0000054215.71691.16. Epub 2003 Feb 3. Hypertension. 2003. PMID: 12623931 Review.
-
Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies.Peptides. 2004 Mar;25(3):521-5. doi: 10.1016/j.peptides.2003.12.010. Peptides. 2004. PMID: 15134871 Review.
Cited by
-
The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.Br J Pharmacol. 2000 Feb;129(4):671-80. doi: 10.1038/sj.bjp.0703109. Br J Pharmacol. 2000. PMID: 10683191 Free PMC article.
-
Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats.Br J Pharmacol. 2000 Jul;130(6):1297-304. doi: 10.1038/sj.bjp.0703442. Br J Pharmacol. 2000. PMID: 10903969 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous